JPRN-jRCTs071180050进行中(未招募)未知
Combination Therapy of SGLT2 Inhibitor and intensive Physical Exercises, focusing on the Prevention of Muscle Mass Reduction in Patients with Type 2 Diabetes - Combination of SGLT2 inhibitor and Intensive Exercise in Diabetes.
Yoshihiro Ogawa0 个研究点目标入组 146 人开始时间: 2019年3月15日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 146
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 age old 至 75 age old(—)
- 性别
- All
入选标准
- •1)Type 2 diabetic patients with age of 20 years old or older but below 75 years old
- •2)Patients whose BMI is 18.5 kg/m2 or higher but below 35.0 kg/m2
- •3)Patients whose HbA1c is 6.5% or higher but below10.0% (examination values of week 0 are to be applicable)
- •4)Patients whose eGFR is 45 mL/min/1.73 m2 or higher
- •5)Patients who have been receiving medications without any change in the administration and dosage for more than 8 weeks prior to the registration
- •6)Patients who can abide by the designated dietary treatment and exercise therapy
- •7)Patients from whom a consent in writing for the participation in this study has been obtained in person
排除标准
- •1) Type 1 diabetic patients
- •2) Patients with a medical history of hypersensitivity to some ingredient(s) of the SGTL2 Inhibitor
- •3) Patients suffering from severe ketosis, diabetic coma, or precoma
- •4) Patients with severe infections, patients before or after operations or having severe external injuries
- •5) Patients with severe renal dysfunction, or patients with end-stage renal disease or those undergoing dialysis
- •6) Patients with severe liver dysfunction
- •7) Patients who are highly likely to suffer from dehydration
- •8) Patients with pituitary gland dysfunction or adrenal gland dysfunction
- •9)Patients in dystrophia conditions, starvation status, irregular meal intake, insufficient dietary intake, or extremely weakened state
- •10) Patients with an excessive alcohol consumption
- •11) Pregnant women, patients who might be pregnant, and lactating women
- •12) Patients with active infectious diseases
- •13) Patients with malignancies
- •14)Patients with active diabetic proliferative retinopathy
- •15) Patients with glucocorticoid
- •16) Patients with insulin
- •17)Patients who have experienced hypoglycemia 3 times or more, which requires a drug treatment such as instillation with glucose before recovery
- •18) Patients who are judged to be inadequate to participate in this study by a doctor in charge
研究者
相似试验
已完成
不适用
Effects of treatment with SGLT2 inhibitor on the initiation of continuous positive airway pressure therapy in type 2 diabetic patients with obstructive sleep apnea syndromeType 2 diabetesJPRN-UMIN000045226Akishima Clinic16
尚未招募
不适用
Effect of SGLT2 inhibitor, Dapagliflozin combined with or without metformin on body composition in patients with type 2 diabetestype 2 diabetes mellitusJPRN-UMIN000030446St. Marianna University School of Medicine54
招募中
不适用
Efficacy and Safety of SGLT2 inhibitors in patients with type 1 diabete.type 1 diabetesJPRN-UMIN000044317Hokkaido University Hospital200
招募中
4 期
Efficacy of SGLT2 inhibitor for Non-Alcoholic Fatty Liver Diseaseon Alcoholic Fatty Liver DiseaseC06.552.241.519C18.452.394.750.149ObesityType 2 Diabetes MellitusRBR-48rxwbCentro Educacional Hyarte
已完成
不适用
The efficacy and safety of SGLT2 inhibitor for non alcholic fatty liver disease in Japanese patients with type 2 diabetesJPRN-UMIN000016306Tokyo Medical and Dental University50
